WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2000/061108    International Application No.:    PCT/GB2000/001418
Publication Date: 19.10.2000 International Filing Date: 13.04.2000
Chapter 2 Demand Filed:    09.11.2000    
A61K 9/16 (2006.01), A61K 31/137 (2006.01)
Applicants: GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB) (For All Designated States Except US).
BONVOISIN, Cecile, Isabelle [FR/FR]; (FR) (For US Only).
LAROCHE, Christophe [FR/FR]; (FR) (For US Only)
Inventors: BONVOISIN, Cecile, Isabelle; (FR).
LAROCHE, Christophe; (FR)
Agent: TEUTEN, Andrew, J.; GlaxoSmithKline, corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB)
Priority Data:
GCC/P/99/126 14.04.1999 BH
9921289.6 10.09.1999 GB
Abstract: front page image
(EN)The present invention relates to novel pharmaceutical aerosol formulations comprising: (A) salmeterol xinafoate in the form of particles coated by spray-drying with at least one surfactant in the absence of any other coating excipient, in suspension in (B) a liquefied propellant gas which is 1, 1, 1, 2, 3, 3, 3-heptafluoro-n-propane or 1, 1, 1, 2-tetrafluoroethane and mixtures thereof for administration particularly by the pulmonary route and to a process for preparing these formulations. It also relates to novel particles suitable for use in such formulations.
(FR)La présente invention concerne de nouvelles préparations pharmaceutiques en aérosol contenant: a) salmétérol xinafoate sous forme de particules enduites par séchage par atomisation avec au moins un tensioactif en l'absence de tout autre excipient d'enrobage, en suspension dans b) un gaz propulseur liquéfié qui est 1,1,1,2,3,3,3-heptafluoro-n-propane ou 1,1,1,2-tétrafluoroéthane ou leurs mélanges, lesdites préparations s'administrant en particulier par voie pulmonaire. L'invention concerne en outre une méthode de production desdites préparations ainsi que de nouvelles particules entrant dans leur composition.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)